Acadia Pharmaceuticals Inc.

ACADIA PHARMACEUTICA Beats on EPS, Stock Up 10.97%

The earnings report shows that ACADIA was able to outperform expectations on EPS, which likely contributed to the stock's positive reaction, rising nearly 11%. However, the lack of revenue figures and guidance leaves some uncertainty about the company's financial trajectory. Investors may be encouraged by the EPS beat, but will be looking for more clarity in future reports.